Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Cancer-Osteocyte NeTwoRk Atlas

Project description

A closer look at metastatic bone disease

Metastatic breast cancer is the leading cause of cancer deaths among women in Europe. It often spreads to the bone, causing serious complications in 75 % of patients. Breast cancer cells can be present in bone marrow at diagnosis, highlighting the need to prevent metastatic growth. Studying this network within hard bone tissue remains challenging. The ERC-funded CONTRA project aims to enhance our understanding of metastatic bone disease by mapping osteocyte networks at the tumour-bone interface at single-cell resolution. Using advanced techniques and expertise in cancer-osteocyte communication and various modelling approaches, it will examine this aspect of the metastatic process. Identifying new therapeutic targets through cancer-osteocyte interactions will potentially transform drug development and treatment.

Objective

Metastatic breast cancer claims the lives of more European women than any other cancer, and is an ever-growing problem in an aging global population that increasingly survives treatment of primary cancer. The most common site for metastatic breast lesions is bone, with 75% of patients experiencing pathological fractures, spinal cord compression or severe bone pain. Crosstalk between cancer cells and osteocytes, which make up more than 90% of our bone cells and form a complex sensing and signalling network throughout our bones, has recently been implicated in this process. As we now know that breast cancer cells are already present in the bone marrow by the time a primary tumour has been diagnosed, preventing growth of the metastatic colony is the most likely target for successful therapeutic development. A number of molecular mechanisms have been proposed, including by my team, to underly the hijacking of osteocyte signalling by breast cancer cells, but as the osteocyte network is buried deep within hard mineralised tissue, mapping signalling and sensation within it has eluded researchers for decades. CONTRA proposes to embark upon frontier research to provide a greater understanding of the key signalling underlying metastatic bone disease, using cutting-edge techniques to map the osteocyte networks at the tumour-bone interface at single-cell resolution for the first time.
I will leverage my expertise in cancer-osteocyte crosstalk, and in vivo, in vitro and in silico modelling of the osteocyte network, to be the first to truly understand this under-studied area of the metastatic cascade.
CONTRA has the potential to revolutionise drug development and treatment of metastatic bone disease by providing a leap forward our ability to study the under-explored role of the osteocyte network in metastatic lesions, leveraging cancer-osteocyte crosstalk to identify new therapeutic targets.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-COG

See all projects funded under this call

Host institution

QUEEN MARY UNIVERSITY OF LONDON
Net EU contribution
€ 1 999 186,00
Address
327 MILE END ROAD
E1 4NS LONDON
United Kingdom
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 999 186,00

Beneficiaries (1)